ZoomMed Inc. has signed an exclusive license agreement regarding the rights to distribute, license and sub-license the ZRx Prescriber in the United States for a consideration of more than $3.5 million, with EvEMR Inc. In consideration of the grant of the license, EvEMR will pay to ZoomMed a cash amount of $1.5 million, will issue to ZoomMed 2 million Preferred shares and 2 million participating, non-voting shares in the capital stock of EvEMR representing an additional 10% of the total economic interest in EvEMR, which economic interest value has not yet been determined.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.65M | |
+9.06% | 33.88B | |
+21.99% | 8.35B | |
+31.37% | 4.24B | |
-30.28% | 2.67B | |
-19.35% | 1.45B | |
-25.64% | 1.33B | |
-33.21% | 1.16B | |
+12.55% | 1B | |
-34.50% | 892M |
- Stock Market
- Equities
- ZMD.H Stock
- News ZoomMed Inc.
- ZoomMed Inc. Signs $3.5 Million Exclusive License Agreement with EvEMR Inc